Serum IL-35 and IL-37 Levels in Pediatrics with Obstructive Sleep Apnea Syndrome

Abstract

目的：探讨儿童OSAS患者血清的IL-35、IL-37的水平。方法：46例新诊断的OSAS患者和35例非呼吸暂停对照者被纳入本研究。人口学资料，既往神经肌肉病、遗传代谢病及药物史，习惯通过标准化问卷获得。所有患者均接受多导睡眠图评估。OSAS组平均年龄6.8 ± 3.3(5~9.5)岁。OSAS组中位呼吸暂停低通气指数为12.5 (6.5~21)，中位体重指数为20.5 (18~24.2)。采用ELISA法检测血清IL-35和IL-37水平。结果：OSAS患者血清IL-35和IL-37水平均明显低于健康人。随着OSAS疾病的程度加重，血清IL-35、IL-37水平进一步降低，其差异也具有统计学意义。结论：本研究提示血清IL-35和IL-37可能是OSAS的新的生物标志物，提示调节这两种细胞因子的表达可能为OSAS的治疗提供新的可能靶点。 Objective: The aim of the present study was to investigate the serum level of IL-35. IL-37 in patients with OSAS. Methods: 46 newly diagnosed pediatrics OSAS patients and 35 non-apneic controls were enrolled in this study. Demographic data, previous history of diseases including metabolic diseases and drugs, and habits were obtained by a standardized questionnaire. All patients underwent polysomnographic evaluation. The mean age was 6.8 ± 3.3 (5~9.5) years in the OSAS group. Median apnea-hypopnea index was 12.5 (6.5~21) and median body mass index was 20.5 (18~24.2) in the OSAS group. Cytokine levels in serum were determined using ELISA. Results: The results showed that serums IL-35 and IL-37 levels were significantly decreased in OSAS patients compared with healthy subjects. The cytokine levels correlated inversely with OSAS severity. Conclusion: The study showed that serums IL-35 and IL-37 might be potentially novel biomarkers for OSAS, suggesting that regulating the expression of the two cytokines may provide a new possible target for the treatment of OSAS.